InterVene

Executive Summary

InterVene, Inc. is a privately held medical device company based in San Francisco, California, focused on developing minimally invasive solutions for venous obstructions. Founded in 2014, the company addresses two major unmet clinical needs: venous in-stent restenosis (ISR) and residual thrombotic occlusions. These conditions represent persistent challenges in venous disease management, often leading to recurrent symptoms and re-interventions. InterVene’s technology aims to provide durable, long-term treatment options by restoring venous patency and preventing restenosis. The company's platform is designed to overcome the limitations of existing stenting approaches, particularly in patients with prior interventions or complex anatomy. While still in the development stage, InterVene has the potential to capture a significant share of the venous intervention market, which is driven by an aging population and increasing prevalence of venous disorders. The company’s progress will hinge on clinical evidence, regulatory pathways, and strategic partnerships to accelerate commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA IDE Approval or Clinical Trial Initiation for Lead Product70% success
• Q2 2027First-in-Human Study Results or Early Feasibility Data50% success
• TBDStrategic Partnership or Licensing Agreement with Larger MedTech Company30% success